Newly patented CRISPR nuclease exhibits high activity in various prokaryotic and eukaryotic organisms Patent now opens up ...
Morning Overview on MSN
AI-guided CRISPR tool aims to make DNA edits more precise and safer
Stanford Medicine researchers have built CRISPR-GPT, a large language model designed to automate the full arc of gene-editing ...
The field of plant biotechnology has quickly evolved with the advent of CRISPR-mediated gene editing, fundamentally transforming the exploration and ...
Zacks Investment Research on MSN
Why CRISPR Therapeutics AG (CRSP) outpaced the stock market today
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $47.09, moving +1.42% from the previous trading session.
CRISPR biosensors are transforming healthcare by detecting biomarkers at attomolar sensitivity, enabling real-time health monitoring through wearable patches and implantable sensors. They continuously ...
CRISPR Therapeutics is targeting multiple difficult-to-treat diseases with several candidates. The company's shares could soar if it delivers consistent clinical and regulatory progress. However, the ...
The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death. The agency has ...
Biotech start-up CRISPR Therapeutics made the announcement this morning. That is, it intends to sell $350 million worth of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results